{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:58:02Z","timestamp":1774076282685,"version":"3.50.1"},"reference-count":95,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2003,1,15]]},"DOI":"10.1001\/jama.289.3.331","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T15:05:58Z","timestamp":1047999958000},"page":"331","source":"Crossref","is-referenced-by-count":74,"title":["Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention"],"prefix":"10.1001","volume":"289","author":[{"given":"Graham C.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliott M.","family":"Antman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"ref-jcc20008-1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/0735-1097(92)90632-W","article-title":"Plaque disruption and the acute coronary syndromes of unstable angina and myocardial infarction: if the substrate is similar, why is the clinical presentation different?","volume":"19","author":"Ambrose","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-2","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1001\/archinte.1996.00440120032004","article-title":"Thrombosis in ischemic heart disease.","volume":"156","author":"Ambrose","year":"1996","journal-title":"Arch Intern Med"},{"key":"ref-jcc20008-3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/01.CIR.104.3.365","article-title":"Current concepts of the pathogenesis of the acute coronary syndromes.","volume":"104","author":"Libby","year":"2001","journal-title":"Circulation"},{"key":"ref-jcc20008-4","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJM198010163031601","article-title":"Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.","volume":"303","author":"DeWood","year":"1980","journal-title":"N Engl J Med"},{"key":"ref-jcc20008-5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/hrt.53.4.363","article-title":"Plaque fissuring\u2014the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina.","volume":"53","author":"Davies","year":"1985","journal-title":"Br Heart J"},{"key":"ref-jcc20008-6","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1161\/01.CIR.73.3.418","article-title":"Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death.","volume":"73","author":"Davies","year":"1986","journal-title":"Circulation"},{"key":"ref-jcc20008-7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0009-8981(99)00231-4","article-title":"Tissue factor in human coronary atherosclerotic plaques.","volume":"291","author":"Ardissino","year":"2000","journal-title":"Clin Chim Acta"},{"key":"ref-jcc20008-8","doi-asserted-by":"publisher","first-page":"18B","DOI":"10.1016\/0002-9149(95)80005-D","article-title":"Activation of blood coagulation by plaque rupture: mechanisms and prevention.","volume":"75","author":"Weitz","year":"1995","journal-title":"Am J Cardiol"},{"key":"ref-jcc20008-9","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1161\/01.CIR.103.18.2310","article-title":"The search for replacements for unfractionated heparin.","volume":"103","author":"Antman","year":"2001","journal-title":"Circulation"},{"key":"ref-jcc20008-10","first-page":"12","article-title":"Pharmacology of low molecular weight heparins.","volume":"16","author":"Harenberg","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"ref-jcc20008-11","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins.","volume":"337","author":"Weitz","year":"1997","journal-title":"N Engl J Med"},{"key":"ref-jcc20008-12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1055\/s-0038-1648866","article-title":"Low molecular weight heparin therapy: is monitoring needed?","volume":"72","author":"Boneu","year":"1994","journal-title":"Thromb Haemost"},{"key":"ref-jcc20008-13","doi-asserted-by":"publisher","first-page":"33L","DOI":"10.1016\/S0002-9149(98)00111-8","article-title":"Monitoring of low-molecular-weight heparins in cardiovascular disease.","volume":"82","author":"Abbate","year":"1998","journal-title":"Am J Cardiol"},{"key":"ref-jcc20008-14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1592\/phco.21.2.218.34112","article-title":"Dosing and monitoring of low-molecular-weight heparins in special populations.","volume":"21","author":"Duplaga","year":"2001","journal-title":"Pharmacotherapy"},{"key":"ref-jcc20008-15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000065238","article-title":"Prolonged anti-factor Xa level in a patient with moderate renal insufficiency receiving enoxaparin.","volume":"22","author":"Bastani","year":"2002","journal-title":"Am J Nephrol"},{"key":"ref-jcc20008-16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/S0002-9378(99)70091-8","article-title":"Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy.","volume":"181","author":"Casele","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"ref-jcc20008-17","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","article-title":"Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (FRAxiparine in Ischaemic Syndrome).","volume":"20","author":"The FRAXIS Investigators","year":"1999","journal-title":"Eur Heart J"},{"key":"ref-jcc20008-18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non\u2013Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial.","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"ref-jcc20008-19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"ref-jcc20008-20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","article-title":"Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC).","volume":"96","author":"Klein","year":"1997","journal-title":"Circulation"},{"key":"ref-jcc20008-21","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non\u2013Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis.","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"ref-jcc20008-22","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0735-1097(00)00648-3","article-title":"Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?","volume":"35","author":"Kaul","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-23","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"ref-jcc20008-24","article-title":"Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial.","author":"Michalis","journal-title":"Am Heart J"},{"key":"ref-jcc20008-25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0167-5273(99)00171-0","article-title":"Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.","volume":"71","author":"Cohen","year":"1999","journal-title":"Int J Cardiol"},{"key":"ref-jcc20008-26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"ref-jcc20008-28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","article-title":"Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.","volume":"90","author":"Merlini","year":"1994","journal-title":"Circulation"},{"key":"ref-jcc20008-29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1055\/s-0037-1614931","article-title":"Low molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.","volume":"79","author":"Ernofsson","year":"1998","journal-title":"Thromb Haemost"},{"key":"ref-jcc20008-30","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1161\/01.ATV.20.9.2162","article-title":"In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris.","volume":"20","author":"Merlini","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref-jcc20008-31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease: Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group.","volume":"347","author":"The FRISC Study Group","year":"1996","journal-title":"Lancet"},{"key":"ref-jcc20008-32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/euhj.2001.2779","article-title":"Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.","volume":"23","author":"Antman","year":"2002","journal-title":"Eur Heart J"},{"key":"ref-jcc20008-33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0140-6736(99)07350-X","article-title":"Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study.","volume":"354","author":"The FRISC II Investigators","year":"1999","journal-title":"Lancet"},{"key":"ref-jcc20008-34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S0140-6736(99)07349-3","article-title":"Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study: Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease Investigators.","volume":"354","author":"The FRISC II Investigators","year":"1999","journal-title":"Lancet"},{"key":"ref-jcc20008-35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0735-1097(96)00447-0","article-title":"Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection: Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.","volume":"29","author":"Lindahl","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0735-1097(01)01501-7","article-title":"Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy.","volume":"38","author":"Lindahl","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non\u2013ST-elevation MI: a method for prognostication and therapeutic decision making.","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"},{"key":"ref-jcc20008-38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0002-9149(02)02517-1","article-title":"Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris\/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.","volume":"90","author":"Fox","year":"2002","journal-title":"Am J Cardiol"},{"key":"ref-jcc20008-39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0268-9499(93)90031-P","article-title":"Prothrombin activation by thrombolytic agents.","volume":"7","author":"Seitz","year":"1993","journal-title":"Fibrinolysis"},{"key":"ref-jcc20008-40","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0735-1097(86)80144-9","article-title":"Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis.","volume":"7","author":"Eisenberg","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0735-1097(87)80194-8","article-title":"Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis.","volume":"10","author":"Eisenberg","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/01.CIR.77.1.142","article-title":"Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.","volume":"77","author":"Fitzgerald","year":"1988","journal-title":"Circulation"},{"key":"ref-jcc20008-43","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1161\/01.CIR.101.23.2690","article-title":"High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (Thrombolysis in Myocardial Infarction) 14.","volume":"101","author":"Coulter","year":"2000","journal-title":"Circulation"},{"key":"ref-jcc20008-44","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1161\/01.CIR.80.6.1718","article-title":"Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator.","volume":"80","author":"Kerins","year":"1989","journal-title":"Circulation"},{"key":"ref-jcc20008-45","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1053\/euhj.2001.3083","article-title":"Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction: the AMI-SK study.","volume":"23","author":"Simoons","year":"2002","journal-title":"Eur Heart J"},{"key":"ref-jcc20008-46","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1161\/hc3101.093866","article-title":"Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).","volume":"104","author":"Ross","year":"2001","journal-title":"Circulation"},{"key":"ref-jcc20008-47","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1161\/01.CIR.0000013402.34759.46","article-title":"Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.","volume":"105","author":"Antman","year":"2002","journal-title":"Circulation"},{"key":"ref-jcc20008-48","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0735-1097(98)00612-3","article-title":"Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction\u2014a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II).","volume":"33","author":"Frostfeldt","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-49","doi-asserted-by":"publisher","first-page":"I12","DOI":"10.1002\/clc.v24:1+","article-title":"The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study.","volume":"24","author":"Wallentin","year":"2001","journal-title":"Clin Cardiol"},{"key":"ref-jcc20008-50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/euhj.1999.1896","article-title":"Accelerated streptokinase and enoxaparine: a new thrombolytic regimen in acute myocardial infarction (the ASENOX study) [abstract].","volume":"21","author":"Tatu-Chitoiu","year":"2000","journal-title":"Eur Heart J"},{"key":"ref-jcc20008-51","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1053\/euhj.2001.2940","article-title":"Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.","volume":"23","author":"Baird","year":"2002","journal-title":"Eur Heart J"},{"key":"ref-jcc20008-53","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban.","volume":"344","author":"Cannon","year":"2001","journal-title":"N Engl J Med"},{"key":"ref-jcc20008-54","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJM199911043411901","article-title":"Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction.","volume":"341","author":"Zijlstra","year":"1999","journal-title":"N Engl J Med"},{"key":"ref-jcc20008-55","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1053\/euhj.2000.2301","article-title":"Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology.","volume":"21","author":"Bertrand","year":"2000","journal-title":"Eur Heart J"},{"key":"ref-jcc20008-56","doi-asserted-by":"publisher","first-page":"228S","DOI":"10.1378\/chest.119.1_suppl.228S","article-title":"Antithrombotic agents in coronary artery disease.","volume":"119","author":"Cairns","year":"2001","journal-title":"Chest"},{"key":"ref-jcc20008-58","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/0002-9149(93)90461-K","article-title":"On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromes.","volume":"71","author":"Melandri","year":"1993","journal-title":"Am J Cardiol"},{"key":"ref-jcc20008-59","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/0049-3848(88)90019-9","article-title":"Does protamine chloride neutralize low molecular weight heparin sufficiently?","volume":"52","author":"Gram","year":"1988","journal-title":"Thromb Res"},{"key":"ref-jcc20008-60","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0002-8703(02)00131-X","article-title":"Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus.","volume":"144","author":"Kereiakes","year":"2002","journal-title":"Am Heart J"},{"key":"ref-jcc20008-61","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0735-1097(97)00094-6","article-title":"Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A.","volume":"29","author":"The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-62","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0735-1097(00)00808-1","article-title":"Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.","volume":"36","author":"Goodman","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-64","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0735-1097(96)00343-9","article-title":"Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial): Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.","volume":"28","author":"Karsch","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-65","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S0002-9149(99)00582-2","article-title":"Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris.","volume":"84","author":"Rabah","year":"1999","journal-title":"Am J Cardiol"},{"key":"ref-jcc20008-66","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1067\/mhj.2002.126115","article-title":"Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study: the Antithrombotic Combination Using Tirofiban and Enoxaparin.","volume":"144","author":"Cohen","year":"2002","journal-title":"Am Heart J"},{"key":"ref-jcc20008-67","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/01.CIR.103.5.658","article-title":"Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris.","volume":"103","author":"Collet","year":"2001","journal-title":"Circulation"},{"key":"ref-jcc20008-68","first-page":"272","article-title":"Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.","volume":"13","author":"Kereiakes","year":"2001","journal-title":"J Invasive Cardiol"},{"key":"ref-jcc20008-69","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1067\/mhj.2002.126118","article-title":"Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb\/IIIa inhibition: results from Platelet IIb\/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).","volume":"144","author":"Mukherjee","year":"2002","journal-title":"Am Heart J"},{"key":"ref-jcc20008-70","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1067\/mhj.2001.113217","article-title":"Dalteparin in combination with abciximab during percutaneous coronary intervention.","volume":"141","author":"Kereiakes","year":"2001","journal-title":"Am Heart J"},{"key":"ref-jcc20008-71","doi-asserted-by":"publisher","first-page":"365A","DOI":"10.1016\/S0735-1097(01)80005-X","article-title":"The use of enoxaparin and IIb\/IIIa antagonists in acute coronary syndromes; including PCI: final results of the NICE 3 study.","volume":"37","author":"Ferguson","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1053\/euhj.2000.2266","article-title":"Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coroanry syndromes: the PEPCI Study [abstract].","volume":"22","author":"Martin","year":"2001","journal-title":"Eur Heart J"},{"key":"ref-jcc20008-73","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0735-1097(02)02531-7","article-title":"A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention.","volume":"40","author":"Choussat","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-74","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1067\/mhj.2001.116959","article-title":"The A-to-Z Trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb\/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.","volume":"142","author":"Blazing","year":"2001","journal-title":"Am Heart J"},{"key":"ref-jcc20008-75","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1067\/mhj.2002.122120","article-title":"The SYNERGY trial: study design and rationale.","volume":"143","author":"The SYNERGY Executive Committee","year":"2002","journal-title":"Am Heart J"},{"key":"ref-jcc20008-76","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0735-1097(01)01344-4","article-title":"ACC\/AHA guidelines for percutaneous coronary intervention: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty).","volume":"37","author":"Smith Jr","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-77","article-title":"Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention\u2014results of the CRUISE study.","author":"Bhatt","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-78","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/0167-4889(85)90177-6","article-title":"Binding and endocytosis of heparin by human endothelial cells in culture.","volume":"845","author":"Barzu","year":"1985","journal-title":"Biochim Biophys Acta"},{"key":"ref-jcc20008-79","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/s-0038-1642434","article-title":"Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.","volume":"71","author":"Young","year":"1994","journal-title":"Thromb Haemost"},{"key":"ref-jcc20008-80","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/0049-3848(85)90244-0","article-title":"Comparative pharmacokinetics of a low molecular weight heparin (PK 10\u00a0169) and unfractionated heparin after intravenous and subcutaneous administration.","volume":"39","author":"Bara","year":"1985","journal-title":"Thromb Res"},{"key":"ref-jcc20008-81","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/0049-3848(93)90233-E","article-title":"Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.","volume":"69","author":"Bara","year":"1993","journal-title":"Thromb Res"},{"key":"ref-jcc20008-82","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0735-1097(94)00360-3","article-title":"Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction.","volume":"25","author":"Merlini","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-83","first-page":"48","article-title":"Physiological function of tissue factor pathway inhibitor and interaction with heparins.","volume":"30","author":"Sandset","year":"2000","journal-title":"Haemostasis"},{"key":"ref-jcc20008-84","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0049-3848(98)00079-6","article-title":"Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.","volume":"91","author":"Hansen","year":"1998","journal-title":"Thromb Res"},{"key":"ref-jcc20008-85","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1046\/j.1365-2141.1998.00770.x","article-title":"Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action.","volume":"101","author":"Hansen","year":"1998","journal-title":"Br J Haematol"},{"key":"ref-jcc20008-86","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0049-3848(00)00351-0","article-title":"Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin.","volume":"100","author":"Hansen","year":"2000","journal-title":"Thromb Res"},{"key":"ref-jcc20008-87","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1161\/01.CIR.99.25.3323","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.","volume":"99","author":"Cella","year":"1999","journal-title":"Circulation"},{"key":"ref-jcc20008-88","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/01.CIR.98.4.294","article-title":"Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin: French Investigators of the ESSENCE Trial.","volume":"98","author":"Montalescot","year":"1998","journal-title":"Circulation"},{"key":"ref-jcc20008-89","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1053\/euhj.2001.2738","article-title":"Enoxaparin attenuates the rise in Von wilebrand factor in patients with ST-segment elevation myocardial infarction treated with fibrinolysis: results from ENTIRE-TIMI 23.","volume":"23","author":"Morrow","year":"2002","journal-title":"Eur Heart J"},{"key":"ref-jcc20008-90","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.","volume":"97","author":"Xiao","year":"1998","journal-title":"Circulation"},{"key":"ref-jcc20008-91","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0049-3848(97)00144-8","article-title":"Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions.","volume":"87","author":"Serra","year":"1997","journal-title":"Thromb Res"},{"key":"ref-jcc20008-92","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1053\/euhj.2002.3257","article-title":"Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.","volume":"23","author":"James","year":"2002","journal-title":"Eur Heart J"},{"key":"ref-jcc20008-94","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0735-1097(97)00258-1","article-title":"Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study.","volume":"30","author":"Kontny","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"ref-jcc20008-95","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","article-title":"Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.","volume":"358","author":"The ASSENT 3 Investigators","year":"2001","journal-title":"Lancet"},{"key":"ref-jcc20008-27","article-title":"The Treatment with Enoxaparin and Tirofiban in Acute Myocardial Infarction (TETAMI) Study","volume-title":"Paper presented at: American Heart Association 75th Scientific Sessions","author":"Cohen","year":"2002"},{"key":"ref-jcc20008-52","article-title":"ASSENT 3 PLUS.","volume-title":"Paper presented at: American Heart Association 75th Scientific Sessions","author":"Wallentin","year":"2002"},{"key":"ref-jcc20008-63","article-title":"Low molecular weight heparin in patients undergoing interventional therapy: the ANGIOFRAX study [in German].","volume-title":"Paper presented at: XXIInd Congress of the European Society of Cardiology","author":"Bassand","year":"2000"},{"key":"ref-jcc20008-93","article-title":"Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndromes Treatment (INTERACT).","volume-title":"Paper presented at: American College of Cardiology 51st Annual Scientific Session","author":"Goodman","year":"2002"},{"key":"ref-jcc20008-57","unstructured":"BraunwaldE, AntmanEM, BeasleyJW, . ACC\/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee of the Management of Patients With Unstable Angina). Available at: http:\/\/www.acc.org\/clinical\/guidelines\/unstable\/unstable.pdf. Accessed November 29, 2002."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/195768\/jcc20008_331_342_1597426187.90795.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T19:03:12Z","timestamp":1597431792000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/195768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1,15]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,1,15]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.289.3.331","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2003,1,15]]}}}